#United Kingdom #Food Safety #Kent #Brains Bioceutical #CBD Isolate

Brains Bioceutical Achieves Pioneering Approval for CBD Isolate

In a significant development for the cannabinoid industry, Brains Bioceutical Corp., a prominent name in the production of natural and GMP-compliant cannabinoid Active Pharmaceutical Ingredients (APIs), has achieved a crucial milestone. The company has received safety approval from both the UK's Food Standards Agency (FSA) and Food Standards Scotland (FSS) for its natural CBD isolate intended for food supplements under the Novel Foods legislation. This recognition positions Brains Bio among a select few companies—only five—who have successfully navigated the stringent Novel Food approval process in the UK.

Setting Industry Standards

Brains Bioceutical's CBD isolate, known for its purity levels exceeding 98% and manufactured in a top-tier GMP facility located in Discovery Park, Kent, UK, boasts undetectable levels of THC, with a sensitivity threshold of just 0.000006%. The company has rigorously backed its product with over three years of stability data, ensuring safety levels are significantly above the FSA’s recommended daily intake.

The approval followed a detailed evaluation by the Advisory Committee on Novel Foods and Processes (ACNFP), which determined that Brains Bio's CBD isolate conforms to the highest safety standards required for the market. Rick Brar, the CEO and Chairman of Brains Bio, shared his enthusiasm about this milestone, stating, "This is a defining moment for Brains Bio and the industry. Consumers demand purity, consistency, and safety, and this approval validates our commitment to delivering pharmaceutical-grade, natural CBD."

A Commitment to Quality

As the market for CBD products continues to expand rapidly, Brains Bioceutical is steadfast in its commitment to quality. The approval marks a significant affirmation of the company’s dedication to providing unparalleled cannabinoid solutions in a market that increasingly prioritizes safety and efficacy. Brains Bio actively reshapes the landscape of CBD offerings by ensuring that its products not only meet but exceed industry regulations.

This approval is not just a regulatory win; it's a competitive edge. With its pioneering status solidified, Brains Bioceutical is poised to lead in the cannabinoid sector, setting benchmarks for other companies in quality, safety, and efficacy.

About Brains Bioceutical Corp.

Brains Bioceutical Corp. is at the forefront of evidence-based and science-led advancements in natural plant-based health and wellness solutions. The company excels in the manufacturing of high-quality natural and pure active pharmaceutical ingredients, benefitting from a unique suite of licenses and registrations that position it advantageously within the complex regulatory framework. With a diversified portfolio that spans the pharmaceutical, medical, and nutraceutical sectors, Brains Bio strategically leverages the rapidly growing cannabinoid market.

As the industry evolves, Brains Bioceutical maintains a dynamic and robust approach to capturing market opportunities while ensuring that its product quality reflects the latest scientific insights and consumer demands.

Conclusion

The approval of Brains Bioceutical's natural CBD isolate is more than just an operational milestone; it signifies the company’s steadfast resolve to uphold the highest standards in cannabinoid production. As awareness and demand for safe and effective CBD products rise, Brains Bio ensures that it remains a trusted supplier in the evolving marketplace. This pivotal moment reaffirms Brains Bioceutical's leadership position and its commitment to producing pharmaceutical-grade, natural cannabinoids, paving the way for innovation in health and wellness solutions.